RegeneRx Biopharmaceuticals, Inc. e tlaleha hore bafuputsi ba bontšitse katleho ea phekolo ea Thymosin Beta 4 (Tβ4) e le phekolo e kopantsoeng khahlanong le hyperglycemia (diabetic) -e leng liphetoho tse bakoang ke lisele tsa corneal epithelial.
"Phuputso ea rona e hlakisa khetlo la pele hore kalafo ea motsoako oa Tβ4 le vasoactive intestinal peptide (VIP) e bapala karolo ea bohlokoa ho laolang botsitso bo tiileng le cytoskeleton rearrangement [ea cornea], e amanang haufi-ufi le sethibelo sa botšepehi. Ho feta moo, Tβ4 e tiisa ka matla karolo ea eona e le phekolo ea tlatsetso bakeng sa litšitiso tsa lefu la tsoekere tse se nang litla-morao, kahoo e nolofatsa bofokoli ba mekhoa ea hona joale ea tlhokomelo ea [mahlo], "ho ea ka sehlopha sa lipatlisiso.
Lipatlisiso li ile tsa hlahisoa sebokeng sa Mokhatlo oa Lipatlisiso ka Pono le Ophthalmology (ARVO) 2022, se neng se tšoaretsoe May 1-4, 2022, Denver, Colorado. Sehlopha sa lipatlisiso se ne se kenyelletsa bo-rasaense le lingaka tsa Wayne State University School of Medicine e Detroit, MI; Univesithi ea Central Florida College of Health of Health Professors and Sciences in Orlando, FL; le Univesithi ea Mansoura e Mansoura, Egepeta. Lipatlisiso li ne li tšehetsoa ka lichelete ke Mekhatlo ea Sechaba ea Bophelo bo Botle, Setsi sa Eversight bakeng sa Pono le Lipatlisiso tsa Banka ea Mahlo, le Lipatlisiso ho Thibela Bofofu.
